S&P 500
(1.26%) 5 127.79 points
Dow Jones
(1.18%) 38 676 points
Nasdaq
(1.99%) 16 156 points
Oil
(-1.22%) $77.99
Gas
(5.65%) $2.15
Gold
(0.02%) $2 310.10
Silver
(-0.16%) $26.79
Platinum
(0.37%) $966.20
USD/EUR
(-0.35%) $0.929
USD/NOK
(-1.07%) $10.87
USD/GBP
(-0.11%) $0.797
USD/RUB
(0.35%) $91.45

实时更新: PureTech Health plc [PRTC]

交易所: NASDAQ 部门: Healthcare 工业: Biotechnology
最后更新时间4 May 2024 @ 04:00

5.06% $ 28.47

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):
Profile picture for PureTech Health plc

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States...

Stats
今日成交量 294.00
平均成交量 2 829.00
市值 769.31M
EPS $0 ( 2023-07-28 )
下一个收益日期 ( $0 ) 2024-06-12
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -11.86
ATR14 $0 (0.00%)

PureTech Health plc 相关性

10 最正相关
NESR0.886
SPLK0.881
SFBC0.866
MRM0.86
ARNA0.856
FSTR0.85
RCII0.848
HBANO0.847
EGLE0.847
TIG0.846
10 最负相关
LMDX-0.874
AEHR-0.868
MHUA-0.86
AVXL-0.859
OFLX-0.856
ETSY-0.855
OSMT-0.853
VMAR-0.853
ZSAN-0.848
ZKIN-0.841

你知道吗?

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。

相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

PureTech Health plc 财务报表

Annual 2023
营收: $3.33M
毛利润: $-1.60M (-48.14 %)
EPS: $-2.38
FY 2023
营收: $3.33M
毛利润: $-1.60M (-48.14 %)
EPS: $-2.38
FY 2022
营收: $2.09M
毛利润: $2.09M (100.00 %)
EPS: $-1.300
FY 2021
营收: $9.98M
毛利润: $0.00 (0.00 %)
EPS: $-2.12

Financial Reports:

No articles found.

PureTech Health plc

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

关于 实时信号

此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。

实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。